Newswire (Published: Friday, November 3, 2017, Received: Friday, October 27, 2017, 12:03:37 AM CDT)

Word Count: 468

Study Findings from University of Toronto Provide New Insights into Prostate Cancer (Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation ...)

By a News Reporter-Staff News Editor at Drug Week -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news originating from Toronto, Canada, by NewsRx correspondents, research stated, "Androgen-deprivation therapy (ADT) is an effective treatment for men with advanced prostate cancer, but loss of bone mineral density (BMD) is a major risk factor for fractures. This review compared the efficacy of available treatments to provide prescribing guidance to healthcare professionals."

Financial support for this research came from Norske Legeforening (see also Oncology - Prostate Cancer).

Our news journalists obtained a quote from the research from the University of Toronto, "This is the first review to compare the effectiveness of different osteoporotic treatments (bisphosphonates, denosumab, toremifene, and raloxifene) on BMD in patients with non-metastatic prostate cancer on ADT using network meta-analysis. Results suggest that all evaluated treatments are effective in improving BMD compared to placebo. Zoledronic acid (ZA) was found to have a greater improvement in BMD compared to other active treatments at all three studied sites, except for risedronate, which had better BMD improvement compared to ZA at the femoral neck site in one small study. Our study did not identify evidence that one drug is unequivocally more effective than another. All drugs appeared to be effective in reducing the rate of bone loss."

According to the news editors, the research concluded: "Healthcare professionals should also consider patient preference, costs, and local availability as part of the decision process."

For more information on this research see: Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. Bju International, 2017;():. (Wiley-Blackwell - www.wiley.com/; Bju International - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1464-410X)

The news correspondents report that additional information may be obtained from Y. Poon, The University of Toronto, Toronto, ON, Canada. Additional authors for this research include P. Pechlivanoglou, S.MH. Alibhai, D. Naimark, J.S. Hoch, E. Papadimitropoulos, M.E. Hogan and M. Krahn.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1111/bju.14015. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Canada, Toronto, Ontario, Oncology, Androgens, Bone Research, Article Review, Prostate Cancer, Drugs and Therapies, Prostatic Neoplasms, Risk and Prevention, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Central America
North America
Canada
Americas
Ontario
Toronto

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies